Chronic lymphocytic leukaemia
- PMID: 18358929
- DOI: 10.1016/S0140-6736(08)60456-0
Chronic lymphocytic leukaemia
Abstract
Chronic lymphocytic leukaemia is the commonest form of leukaemia in Europe and North America, and mainly, though not exclusively, affects older individuals. It has a very variable course, with survival ranging from months to decades. Major progress has been made in identification of molecular and cellular markers that could predict disease progression in patients with chronic lymphocytic leukaemia. In particular, the mutational profile of immunoglobulin genes and some cytogenetic abnormalities are important predictors of prognosis. However, these advances have raised new questions about the biology, prognosis, and management of chronic lymphocytic leukaemia, some of which are addressed here. In particular, we discuss how better understanding of the function of the B-cell receptor, the nature of genetic lesions, and the balance between proliferation and apoptosis have affected our ability to assess prognosis and to manage chronic lymphocytic leukaemia. Available treatments generally induce remission, although nearly all patients relapse, and chronic lymphocytic leukaemia remains an incurable disease. Advances in molecular biology have enhanced our understanding of the pathophysiology of the disease and, together with development of new therapeutic agents, have made management of chronic lymphocytic leukaemia more rational and more effective than previously. Unfortunately, we know of no way that chronic lymphocytic leukaemia can be prevented. Early detection is practised widely, but seemingly makes no difference to the patient's eventual outcome.
Similar articles
-
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.Expert Rev Anticancer Ther. 2006 Dec;6(12):1787-800. doi: 10.1586/14737140.6.12.1787. Expert Rev Anticancer Ther. 2006. PMID: 17181492 Review.
-
Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.Haematologica. 1999 Jun;84 Suppl EHA-4:94-5. Haematologica. 1999. PMID: 10907481 Review. No abstract available.
-
Risk stratification in chronic lymphocytic leukemia.Semin Oncol. 2006 Apr;33(2):186-94. doi: 10.1053/j.seminoncol.2006.01.017. Semin Oncol. 2006. PMID: 16616065 Review.
-
Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.Oncology (Williston Park). 2003 Feb;17(2):253-62; discussion 264, 267, passim. Oncology (Williston Park). 2003. PMID: 12632866 Review.
-
Treatment options in chronic lymphocytic leukemia.Hematol J. 2004;5 Suppl 1:S2-9. doi: 10.1038/sj.thj.6200386. Hematol J. 2004. PMID: 15079148 Review.
Cited by
-
Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.Cell Oncol (Dordr). 2015 Apr;38(2):93-109. doi: 10.1007/s13402-014-0215-3. Epub 2015 Jan 7. Cell Oncol (Dordr). 2015. PMID: 25563586 Review.
-
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans.Blood. 2012 Aug 23;120(8):1687-90. doi: 10.1182/blood-2012-02-408799. Epub 2012 Jun 28. Blood. 2012. PMID: 22745306 Free PMC article.
-
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13. Blood. 2013. PMID: 23243274 Free PMC article.
-
p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.Haematologica. 2019 Oct;104(10):2040-2052. doi: 10.3324/haematol.2018.209981. Epub 2019 Feb 28. Haematologica. 2019. PMID: 30819907 Free PMC article.
-
The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.Oncologist. 2011;16(9):1280-91. doi: 10.1634/theoncologist.2010-0349. Epub 2011 Jul 7. Oncologist. 2011. PMID: 21737576 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources